Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan Exits Noctiva Partnership With Serenity Just As FDA Approves Controversial Drug

Executive Summary

Just as Noctiva obtains FDA approval as the first drug for nocturia due to nocturnal polyuria, Allergan bails on collaboration signed seven years ago.

Advertisement

Related Content

Deal Watch: Troubled Antibiotics Maker Cempra Exploring Strategic Options
Amid Pricing Criticism, Marathon 'Pausing' Emflaza Launch
Allergan’s Nasal Spray For Frequent Nighttime Urination Gets Cautious Panel Nod
Allergan Buys Global Rights To Serenity's Phase III Drug For Frequent Nighttime Urination

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC098358

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel